Umberto Capitanio(@u_capitanio) 's Twitter Profileg
Umberto Capitanio

@u_capitanio

Father of two beauties...

ID:1055222041

calendar_today02-01-2013 14:17:54

807 Tweets

891 Followers

215 Following

RobertoRedSox(@RobertoRedSox) 's Twitter Profile Photo

All’arrivo il tassametro segna 10.45
-Vorrei pagare con carta

[Sbuffa]

-Deve aspettare che accenda il POS… contante non ce la fate?

[e intanto non blocca tassametro]

-Eh no, carta grazie
Continua a non bloccare il tassametro, quindi nel pos digita la cifra di 11€

Simpatia

All’arrivo il tassametro segna 10.45 -Vorrei pagare con carta [Sbuffa] -Deve aspettare che accenda il POS… contante non ce la fate? [e intanto non blocca tassametro] -Eh no, carta grazie Continua a non bloccare il tassametro, quindi nel pos digita la cifra di 11€ Simpatia
account_circle
Francesco Cei(@francesco_cei1) 's Twitter Profile Photo

Our team has developed a new model that accurately predicts partial nephrectomy outcomes based on patient data, tumor complexity, and surgical approach. 🔗 Check out our results: shorturl.at/cxFK9
A huge thank you to all co-authors and mentors for their contributions! 🙏

Our team has developed a new model that accurately predicts partial nephrectomy outcomes based on patient data, tumor complexity, and surgical approach. 🔗 Check out our results: shorturl.at/cxFK9 A huge thank you to all co-authors and mentors for their contributions! 🙏
account_circle
Olivier Traxer(@OTRAXER) 's Twitter Profile Photo

BN128: Congratulations Dr E. VENTIMIGLIA! Your manuscript : 'High & Low-Power Laser
Lithotripsy Achieves Similar Results:
A Systematic Review…'
was the Top Cited paper in J. Endourol. You will be recognized at «J.EndoUrol Editorial Board Reception» May5h (6pm) Grand Hyatt, AUA24

BN128: Congratulations Dr E. VENTIMIGLIA! Your manuscript : 'High & Low-Power Laser Lithotripsy Achieves Similar Results: A Systematic Review…' was the Top Cited paper in J. Endourol. You will be recognized at «J.EndoUrol Editorial Board Reception» May5h (6pm) Grand Hyatt, AUA24
account_circle
Chiara Re(@ChiaraRe) 's Twitter Profile Photo

Truly honoured to receive this recognition!

Thanks to all the BJU International Editorial Board.

Special thanks to Grant Stewart for his daily mentorship & inspiration!

bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.11…

Truly honoured to receive this recognition! Thanks to all the @BJUIjournal Editorial Board. Special thanks to @grantissimus for his daily mentorship & inspiration! bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.11…
account_circle
Grant Stewart(@grantissimus) 's Twitter Profile Photo

A fantastic day today with Toni Choueiri, MD and his superb team in clinic Dana-Farber, Toni is not only a researcher par excellence but a great and caring doctor whose patients' love him! Looking forward to research discussions tomorrow. CRUK Cambridge Centre: Urological Malignancies JamesIVAssociation

A fantastic day today with @DrChoueiri and his superb team in clinic @DanaFarber, Toni is not only a researcher par excellence but a great and caring doctor whose patients' love him! Looking forward to research discussions tomorrow. @CRUKCamUrol @JamesIVAssoc
account_circle
Paolo Capogrosso(@Paolo_Capog) 's Twitter Profile Photo

Truly honored to be appointed as Chair of the Scientific Committee for the European Society of Sexual Medicine. Looking forward to advancing research and knowledge in this important field!
European Society for Sexual Medicine (ESSM) Uninsubria

Truly honored to be appointed as Chair of the Scientific Committee for the European Society of Sexual Medicine. Looking forward to advancing research and knowledge in this important field! @essm_tweets @Uni_Insubria
account_circle
Tom Powles(@tompowles1) 's Twitter Profile Photo

With a median FU up of ~5 yrs adjuvant pembro= 38% reduction in risk of death. The benefit is across subgroups (T stage etc). Subsequent therapy in 80% is relapses. The 1st +ve OS adjuvant PD1 study, making adjuvant pembro more attractive. Toni Choueiri, MD

With a median FU up of ~5 yrs adjuvant pembro= 38% reduction in risk of death. The benefit is across subgroups (T stage etc). Subsequent therapy in 80% is relapses. The 1st +ve OS adjuvant PD1 study, making adjuvant pembro more attractive. #GU24 @DrChoueiri
account_circle
Alessandro Larcher(@_alelarcher) 's Twitter Profile Photo

Removing Barriers to the Use of Systemic Agents for Patients with von Hippel-Lindau Disease: hot of the press report of surveillance data from the Ospedale San Raffaele Program assessing generalizability of the MK-6482-004 trial.
authors.elsevier.com/c/1iU9b9Cfv--d…

Removing Barriers to the Use of Systemic Agents for Patients with von Hippel-Lindau Disease: hot of the press report of surveillance data from the @SanRaffaeleMI #VHL Program assessing generalizability of the MK-6482-004 trial. authors.elsevier.com/c/1iU9b9Cfv--d…
account_circle
RobertoRedSox(@RobertoRedSox) 's Twitter Profile Photo

Vi presento un esempio di tassista romano (ma gli attacchi personali arrivano da tutta Italia) ossessionato dalla mia campagna di trasparenza che li sta obbligando a dichiarare di più.
Tipico italiano evasore che PRETENDE di continuare a vivere col sistema di sempre, col nero

account_circle
James Brugarolas(@JBrugarolas) 's Twitter Profile Photo

Belzutifan developed by spinoff Peloton approved for sporadic culminating 25 year KidneyCancerProgram journey starting from HIF2a gene discovery with National Cancer Institute SPORE funding bit.ly/BelzutifanAppr… based on led by Toni Choueiri, MD presented at ESMO - Eur. Oncology Laurence Albiges approved by

account_circle
RobertoRedSox(@RobertoRedSox) 's Twitter Profile Photo

Intervento alla Camera di Mauro Berruto che ringrazio immensamente.
Sono ancora più motivato a fare bene e a sperare in bene.

A tal dégg 👊 🚕

account_circle